JP2019519215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519215A5 JP2019519215A5 JP2018560491A JP2018560491A JP2019519215A5 JP 2019519215 A5 JP2019519215 A5 JP 2019519215A5 JP 2018560491 A JP2018560491 A JP 2018560491A JP 2018560491 A JP2018560491 A JP 2018560491A JP 2019519215 A5 JP2019519215 A5 JP 2019519215A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- cell
- cells
- pharmaceutical composition
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338757P | 2016-05-19 | 2016-05-19 | |
| US62/338,757 | 2016-05-19 | ||
| US201762471456P | 2017-03-15 | 2017-03-15 | |
| US62/471,456 | 2017-03-15 | ||
| PCT/US2017/033585 WO2017201432A2 (en) | 2016-05-19 | 2017-05-19 | Tethered interleukin-2 to its receptor il-2rbeta, a platform to enhance natural killer and regulatory t cell activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519215A JP2019519215A (ja) | 2019-07-11 |
| JP2019519215A5 true JP2019519215A5 (enExample) | 2020-07-02 |
| JP7178906B2 JP7178906B2 (ja) | 2022-11-28 |
Family
ID=60326626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560491A Active JP7178906B2 (ja) | 2016-05-19 | 2017-05-19 | ナチュラルキラー細胞および制御性Ｔ細胞の活性を強化するためのプラットフォームである、その受容体ＩＬ－２Ｒβに繋ぎ止められたインターロイキン－２ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12202856B2 (enExample) |
| EP (1) | EP3458485B1 (enExample) |
| JP (1) | JP7178906B2 (enExample) |
| CN (1) | CN109689694B (enExample) |
| WO (1) | WO2017201432A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019018915A2 (pt) | 2017-03-15 | 2020-04-14 | Pandion Therapeutics Inc | imunotolerância direcionada |
| AU2018273914A1 (en) | 2017-05-24 | 2019-11-14 | Pandion Operations, Inc. | Targeted immunotolerance |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| US12280119B2 (en) | 2018-03-23 | 2025-04-22 | Kite Pharma, Inc. | Chimeric transmembrane proteins and uses thereof |
| PE20210313A1 (es) | 2018-03-28 | 2021-02-12 | Bristol Myers Squibb Co | Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso |
| SG11202009975TA (en) * | 2018-04-12 | 2020-11-27 | Umoja Biopharma Inc | Viral vectors and packaging cell lines |
| WO2020023702A1 (en) | 2018-07-25 | 2020-01-30 | AskGene Pharma, Inc. | Novel il-21 prodrugs and methods of use thereof |
| AU2020279240A1 (en) | 2019-05-20 | 2021-12-23 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| CN114341189A (zh) | 2019-06-12 | 2022-04-12 | 奥美药业有限公司 | 全新il-15前药及其应用 |
| EP4013775A1 (en) * | 2019-08-12 | 2022-06-22 | Askgene Pharma, Inc. | Il-2 fusion proteins that preferentially bind il-2ralpha |
| US11414852B2 (en) * | 2019-09-22 | 2022-08-16 | Bio Clean Environmental Services, Inc. | Removable trash filter basket with hinged wier for catch basins |
| IL293978A (en) | 2019-12-20 | 2022-08-01 | Regeneron Pharma | New il2 agonists and methods of using them |
| AU2021205981A1 (en) | 2020-01-11 | 2022-07-14 | AskGene Pharma, Inc. | Novel masked cytokines and methods of use thereof |
| US11981715B2 (en) | 2020-02-21 | 2024-05-14 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a CD39 effector |
| WO2021207290A1 (en) * | 2020-04-06 | 2021-10-14 | Synthekine, Inc. | Engineered immune cells |
| CN112266413A (zh) * | 2020-10-22 | 2021-01-26 | 中国人民解放军海军军医大学 | 扩增nk细胞并增强其杀伤活性的因子、饲养细胞系及方法 |
| US12012441B2 (en) | 2020-10-26 | 2024-06-18 | Neptune Biosciences Llc | Engineered human IL-21 cytokines and methods for using the same |
| CN117915930A (zh) * | 2021-04-28 | 2024-04-19 | 总医院公司 | 与其受体IL-2Rβ结合的IL2以及成孔蛋白作为增强免疫细胞活性的平台 |
| TW202317623A (zh) | 2021-06-14 | 2023-05-01 | 美商再生元醫藥公司 | 基於il2之治療劑及其使用方法 |
| CN116421626A (zh) * | 2022-01-04 | 2023-07-14 | 京东方再生医学科技有限公司 | Nk细胞制备方法及其用途 |
| CN114875069B (zh) * | 2022-04-22 | 2023-09-15 | 四川大学 | 基因工程修饰的il2细胞因子的重组载体、宿主细胞及其用途 |
| EP4577222A2 (en) * | 2022-08-26 | 2025-07-02 | Sonoma Biotherapeutics, Inc. | Tethered interleukin-2 recombinant receptors and methods of use |
| JP2026507781A (ja) | 2023-01-23 | 2026-03-06 | メディツィニシェ ホゥーシュル ハノーファー | キメラ抗原受容体 |
| EP4403580A1 (en) | 2023-01-23 | 2024-07-24 | Medizinische Hochschule Hannover | Anti-entpd3 chimeric antigen receptor |
| CN120787258A (zh) | 2023-02-07 | 2025-10-14 | 圭尔医疗有限公司 | Treg细胞培养方法 |
| EP4420676A1 (en) | 2023-02-24 | 2024-08-28 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024175805A1 (en) | 2023-02-24 | 2024-08-29 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| EP4434539A1 (en) | 2023-03-20 | 2024-09-25 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2024194355A1 (en) | 2023-03-20 | 2024-09-26 | Medizinische Hochschule Hannover | Chimeric antigen receptor |
| WO2025090939A1 (en) * | 2023-10-26 | 2025-05-01 | The General Hospital Corporation | Self-activating il15 chimeric cytokine receptors |
| US20260176598A1 (en) | 2024-07-04 | 2026-06-25 | Quell Therapeutics Limited | Expression construct |
| GB202411558D0 (en) | 2024-08-06 | 2024-09-18 | Quell Therapeutics Ltd | Culture method |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU695869B2 (en) | 1993-04-06 | 1998-08-27 | Fred Hutchinson Cancer Research Center | Chimeric cytokine receptors in lymphocytes |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US8034332B2 (en) | 1997-04-30 | 2011-10-11 | Conkwest, Inc. | Interleukin-secreting natural killer cell lines and methods of use |
| DE69834257T2 (de) | 1997-04-30 | 2007-01-04 | Klingemann, Hans | Natürliche killerzelllinien und verfahren zu ihrer verwendung |
| US6645490B2 (en) | 1998-03-02 | 2003-11-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Chimeric proteins with cell-targeting specificity and apoptosis-inducing activities |
| DZ2788A1 (fr) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| NZ517202A (en) | 1999-08-24 | 2004-05-28 | Medarex Inc | Human CTLA-4 antibodies and their uses |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| DE60035057T2 (de) | 1999-10-04 | 2008-01-31 | Novartis Vaccines and Diagnostics, Inc., Emeryville | CD40 Antagonist zur Behandlung von Psoriasis |
| US20030059427A1 (en) | 2000-04-28 | 2003-03-27 | Force Walker R. | Isolation and characterization of highly active anti-CD40 antibody |
| CA2658221C (en) | 2001-04-27 | 2012-11-27 | Kyowa Kirin Co., Ltd. | Anti-cd40 monoclonal antibody |
| WO2002088346A2 (en) | 2001-05-01 | 2002-11-07 | National Research Council Of Canada | A system for inducible expression in eukaryotic cells |
| DE60334303D1 (de) | 2002-07-03 | 2010-11-04 | Tasuku Honjo | Immunpotenzierende zusammensetzungen |
| US7276478B2 (en) | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| US8277810B2 (en) | 2003-11-04 | 2012-10-02 | Novartis Vaccines & Diagnostics, Inc. | Antagonist anti-CD40 antibodies |
| CN100379762C (zh) | 2003-12-08 | 2008-04-09 | 中国人民解放军军事医学科学院生物工程研究所 | 人血清白蛋白与白细胞介素2的融合蛋白及其编码基因 |
| EP1707627B1 (en) | 2003-12-25 | 2012-11-14 | Kyowa Hakko Kirin Co., Ltd. | Antagonistic anti-CD40 antibody mutant |
| US7674621B2 (en) | 2004-05-21 | 2010-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | Plasmids and phages for homologous recombination and methods of use |
| ES2678094T3 (es) | 2004-07-10 | 2018-08-08 | Fox Chase Cancer Center | Líneas de células asesinas naturales genéticamente modificadas |
| WO2006076742A2 (en) | 2005-01-16 | 2006-07-20 | Georgia Tech Research Corporation | Methods and compositions for increasing membrane permeability |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| SMP200800064B (it) | 2006-04-21 | 2009-11-06 | Novartis Ag | Composizioni farmaceutiche di anticorpi anti-cd40 antagonista |
| JP5372751B2 (ja) | 2006-07-21 | 2013-12-18 | ギリアード サイエンシーズ， インコーポレイテッド | Ａｚａ−ペプチドプロテアーゼ阻害剤 |
| US20090025274A1 (en) | 2007-07-23 | 2009-01-29 | Tim Lail | Animal trap |
| GB0815216D0 (en) * | 2008-08-21 | 2008-09-24 | Asterion Ltd | Interleukin |
| WO2010036959A2 (en) | 2008-09-26 | 2010-04-01 | Dana-Farber Cancer Institute | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor |
| EP2796467B1 (en) | 2010-03-31 | 2018-03-28 | Boehringer Ingelheim International GmbH | Anti-CD40 antibodies |
| US8734774B2 (en) | 2010-04-02 | 2014-05-27 | University Of Rochester | Protease activated cytokines |
| CN103079644B (zh) | 2010-06-11 | 2017-02-15 | 协和发酵麒麟株式会社 | 抗tim‑3抗体 |
| ES2734076T3 (es) | 2011-02-17 | 2019-12-04 | Kyowa Hakko Kirin Co Ltd | Preparación farmacéutica de anticuerpo anti-CD40 muy concentrada |
| KR102037432B1 (ko) | 2011-04-29 | 2019-11-27 | 아펙시젠, 인코포레이티드 | 항-cd40 항체 및 사용 방법 |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| BR112014012819B1 (pt) | 2011-11-28 | 2022-08-16 | Merck Patent Gmbh | Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição |
| US9844582B2 (en) | 2012-05-22 | 2017-12-19 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents |
| CA2888763A1 (en) | 2012-10-30 | 2014-05-08 | Apexigen, Inc. | Anti-cd40 antibodies and methods of use |
| SG11201507026WA (en) * | 2013-02-06 | 2015-10-29 | Anthrogenesis Corp | Modified t lymphocytes having improved specificity |
| AU2014276440A1 (en) | 2013-06-03 | 2015-11-05 | Novartis Ag | Combinations of an anti-PD-L1 antibody and a MEK inhibitor and/or a BRaf inhibitor |
| US10550197B2 (en) | 2014-06-18 | 2020-02-04 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | CAR-expressing NK-92 cells as cell therapeutic agents |
| CN106604933B (zh) | 2014-07-11 | 2021-08-10 | 文塔纳医疗系统公司 | 抗pd-l1抗体及其诊断用途 |
| MA40094B1 (fr) | 2014-08-06 | 2022-05-31 | Univ Miami | Protéines de fusion de l'interleukine-2/récepteur alpha de l'interleukine-2 et procédés d'utilisation |
| JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
| SG11201702401RA (en) | 2014-10-14 | 2017-04-27 | Novartis Ag | Antibody molecules to pd-l1 and uses thereof |
| MY193661A (en) | 2014-11-06 | 2022-10-24 | Hoffmann La Roche | Anti-tim3 antibodies and methods of use |
| CA2974998C (en) * | 2015-02-12 | 2022-04-26 | Takara Bio Inc. | Chimeric antigen receptors |
| AU2016229189A1 (en) | 2015-03-06 | 2017-09-21 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
| CN114533867A (zh) | 2015-03-27 | 2022-05-27 | 免疫生物公司 | 用于治疗癌症的被遗传修饰的nk-92细胞和单克隆抗体 |
| AU2016252038B2 (en) | 2015-04-20 | 2021-08-12 | Effector Therapeutics, Inc. | Inhibitors of immune checkpoint modulators for use in treating cancer and infections |
| CN114853891A (zh) | 2015-07-22 | 2022-08-05 | 索伦托药业有限公司 | 与lag3结合的抗体治疗剂 |
| EP3331919A1 (en) | 2015-08-07 | 2018-06-13 | GlaxoSmithKline Intellectual Property Development Limited | Combination therapy comprising anti ctla-4 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| LU92821B1 (en) | 2015-09-09 | 2017-03-20 | Mologen Ag | Combination comprising immunostimulatory oligonucleotides |
| MA43028B1 (fr) | 2015-10-02 | 2021-09-30 | Hoffmann La Roche | Anticorps bispécifiques pour pd1 et tim3 |
| TWI756187B (zh) | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | 抗ｌａｇ３抗體及其用途 |
| JP7198670B2 (ja) * | 2016-04-20 | 2023-01-04 | フレッド ハッチンソン キャンサー センター | 免疫調整性ｉｌ２ｒ融合タンパク質およびその使用 |
| EP3848393A1 (en) | 2016-05-18 | 2021-07-14 | Boehringer Ingelheim International GmbH | Antibody molecules for cancer treatment |
| US20190248893A1 (en) | 2016-07-14 | 2019-08-15 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| CN111050788A (zh) | 2017-02-28 | 2020-04-21 | 西雅图基因公司 | 抗tigit抗体 |
| CA3052532A1 (en) | 2017-04-05 | 2018-10-11 | F. Hoffmann-La Roche Ag | Bispecific antibodies specifically binding to pd1 and lag3 |
| JP2020532987A (ja) | 2017-09-08 | 2020-11-19 | ポセイダ セラピューティクス，インコーポレイティド | キメラリガンド受容体（ｃｌｒ）介在性の条件遺伝子発現のための組成物および方法 |
| EP3841123A2 (en) | 2018-08-23 | 2021-06-30 | Seagen Inc. | Anti-tigit antibodies |
| CN117915930A (zh) | 2021-04-28 | 2024-04-19 | 总医院公司 | 与其受体IL-2Rβ结合的IL2以及成孔蛋白作为增强免疫细胞活性的平台 |
-
2017
- 2017-05-19 US US16/302,001 patent/US12202856B2/en active Active
- 2017-05-19 EP EP17800257.2A patent/EP3458485B1/en active Active
- 2017-05-19 JP JP2018560491A patent/JP7178906B2/ja active Active
- 2017-05-19 WO PCT/US2017/033585 patent/WO2017201432A2/en not_active Ceased
- 2017-05-19 CN CN201780044474.8A patent/CN109689694B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Maggs et al. | CAR T cell-based immunotherapy for the treatment of glioblastoma | |
| Duan et al. | The BCMA-targeted fourth-generation CAR-T cells secreting IL-7 and CCL19 for therapy of refractory/recurrent multiple myeloma | |
| Suarez et al. | Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model | |
| JP2021040652A (ja) | Ｇタンパク質共役受容体を標的化するキメラ抗原受容体およびその使用 | |
| IL259120A (en) | Her2-targeted antigen chimeric receptors2 | |
| JP2020040969A5 (enExample) | ||
| JP2018529363A5 (enExample) | ||
| HRP20190472T1 (hr) | Klaudin-6 specifični imunoreceptori i t-stanični epitopi | |
| JP2017538401A5 (enExample) | ||
| JP2020508329A5 (enExample) | ||
| JP2019520591A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| IL258029B (en) | Compounds and methods for joining extracellular complexes of type 1 and 2 as heterologous chimeric proteins | |
| JP2018514204A (ja) | ガンマデルタｔ細胞受容体（ｔｃｒ）とキメラ抗原受容体（ｃａｒ）とを発現するｔ細胞 | |
| CN107082812A (zh) | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 | |
| Annesley et al. | The evolution and future of CAR T cells for B‐cell acute lymphoblastic leukemia | |
| JP2016530889A (ja) | Ｈｂｖ感染および関連症状の治療のための免疫エフェクター細胞表面抗原およびｈｂｖ抗原結合性の二重特異性または多重特異性ポリペプチド | |
| CN107922489A (zh) | κ骨髓瘤抗原嵌合性抗原受体和其用途 | |
| Jin et al. | Enhance anti-lung tumor efficacy of chimeric antigen receptor-T cells by ectopic expression of C–C motif chemokine receptor 6 | |
| WO2016180034A1 (zh) | 抗ctla-4和pd-1的双重可变结构域免疫球蛋白 | |
| US20200270574A1 (en) | CD1d and TCR-NKT Cells | |
| JP2019530441A5 (enExample) | ||
| US20240424096A1 (en) | IL-10 Expressing Cells For Enhanced Cancer Immunotherapies | |
| US12473346B2 (en) | A2/NY-ESO-1 specific t cell receptors and uses thereof | |
| WO2019136273A1 (en) | Reprogrammed t cell-like nk cells |